Member Info for 13martyn13

Well I'm very pleased with the share price since the suspension was lifted, 8p back to 40p bid is quite achievement.

When WPHO was covered by chartist Zak Mir on Twitter he had a 40p target, not really big understander of charts myself, but amazing how these guys get it right.

Now looking for the next catalyst, could that be the doubling of production Windar are hopefully pulling off.

Not as large a premium as the last time the cap came round.

Removes the funding issue for a while at least, we just need sales.

Indeed, potential RTO candidates down to two.

All sounds very positive, thanks for posting.

Moving up nicely today, maybe someone just took advantage of the rise to sell?

A couple of 25,000 trades in grey, so could mean anything really.

But happy with a move up, just need a little press coverage now.

Nice bit of coverage from Midas in the Mail this weekend, all positive.

Averaged up with 10,000 at 83p this afternoon in anticipation of an improving forward looking statement when the finals get released early July.

Back into three figures would be a great start.

And another 100,000 bought by Paul Hodges, a Non-Executive Director of the Company, had purchased 100,000 Ordinary Shares of 1 pence each ("Ordinary Shares") in the Company at a price of 31 pence each.

Following this transaction, Mr Hodges is interested in 1,381,818 Ordinary Shares in the Company, representing 2.0 per cent of the issued share capital of the Company.

100,000 bought at 30p yesterday near the close.

Interested to see if the 100,000 buy order is still there today, as someone has had an order for 100,000 shares at 26p sitting there for a few days now, or was it the director, and he’s been forced to pay 30p instead of 26p, we’ll see later.

It may have taken a week to sink in but 30p paid today, certainly going in the right direction now.

Hopefully WPHO can hold the gains.

Seems encouraging,

“Entering 2023, the production capacity of the Group was fully booked by customer orders for deliveries in the first half of 2023. Currently, the Group is focused on increasing capacity by at least 100% to be implemented mid-year 2023 and planning for a further doubling of capacity when entering year 2024”

So the DD sale was actually a buy, that’s more like it.

Yes agreed, 300+ test to date, not monthly.

What is obvious is the build up in repeat orders, which must be happening having 300 tests from 20+ oncologists.

The test was initially launched in the US in February 2022. During the period, in November 2022, we hit the key milestone of 100 CiRT tests ordered, around nine months after launch. The next 100 tests were ordered in about half that time and we recently processed the 300th order less than three months later, in mid-May 2023. The period ended with a total of 24 US oncologists 'on the books', 20 of whom had placed orders for CiRT tests since the beginning of 2023 and we have continued to grow our physician base post-period end.

"the average amount paid for reimbursed tests to date is between $2,000 and $2,500, against a list price of $5,500".

Hi bottom_feeder.

“So all in all it looks like OBD is going to shut up shop”

That’s seems a massive assumption going on todays RNS.

We could instead highlight the beginning of Dr Jon Burrows statement…

“The first half of our financial year saw excellent progress across the business.

There was sustained growth in orders of Episwitch Cirt tests, which has continued post-period end. Overwhelming demand for the PSE blood test after the announcement of its high accuracy performance led the group to accelerate its development”.

Hardly comments of a company ready to “shut up shop”.

Yes OBD have spent a lot of the funds raised, but as stated the US subsidiary has leased and moved into 7800 sq ft of laboratory space, these extra costs should not be repeated.

UK clinical lab is also under development, costs of which will not be repeated.

New sales and operation roles in the US and new roles in the UK, which should generate income.

£900,000 in UK tax credits received in April to add to the cash balance.

300,000 EpiSwitch tests processed in May, (which still has 1 day to go).

As the BOD states, the going concern statement was said in the annual reports in 2021 & 2022, and repeat today.

Seems like cash will be needed, “shutting up shop” far from the truth from my reading.

It’s the going concern statement that worries people, but the Bod are required to point out the obvious.

ST recommended these in today’s Alpha article, reads well, I personally wasn’t aware of them before, happy to see you’re invested here Guitarsolo.

I’ve picked up some mainly for the dividend income.

Further, the Company announces that the Broker Option announced on 11 May 2023 has now closed. No shares will be issued under the Broker Option.

Kc911, it’s painful isn’t it :-)

Suspension, not the best outcome, but in real terms is only 8 working days, after taking into account two bank holidays and weekends.
I have sold half at 115.9238p this morning though.